TDI-10229 (C007B-430621)

TDI-10229 is a potent and orally bioavailable inhibitor of soluble adenylyl cyclase (sAC, ADCY10) . TDI-10229 displays nanomolar inhibition of sAC in both biochemical and cellular assays ( IC 50 of 195 nM) and exhibits mouse pharmacokinetic properties sufficient to warrant its use as an in vivo tool compoundIn VitroTDI-10229 exhibits good permeability with an IC 50 of 92 nM for human 4-4 cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoTDI-10229 (5 mg/kg; p.o.) treatment shows the C max , AUC and MRT were 15.5 μM, 94 μg h/mL and 3.95 hours, respectively. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: MouseDosage: 20 mg/kg Administration: P.o.(Pharmacokinetic Analysis) Result: The C max , AUC and MRT were 15.5 μM, 94 μg h/mL and 3.95 hours, respectively.Form:SolidIC50& Target:IC 50 : 195 nM (sAC).

Specifications and Purity: ≥99%

Molecular Formula: C16H16ClN5

Molecular Weight: 313.78